JPWO2023229032A5 - - Google Patents

Info

Publication number
JPWO2023229032A5
JPWO2023229032A5 JP2024523363A JP2024523363A JPWO2023229032A5 JP WO2023229032 A5 JPWO2023229032 A5 JP WO2023229032A5 JP 2024523363 A JP2024523363 A JP 2024523363A JP 2024523363 A JP2024523363 A JP 2024523363A JP WO2023229032 A5 JPWO2023229032 A5 JP WO2023229032A5
Authority
JP
Japan
Prior art keywords
therapeutic
agent according
prophylactic agent
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523363A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023229032A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/019755 external-priority patent/WO2023229032A1/ja
Publication of JPWO2023229032A1 publication Critical patent/JPWO2023229032A1/ja
Publication of JPWO2023229032A5 publication Critical patent/JPWO2023229032A5/ja
Pending legal-status Critical Current

Links

JP2024523363A 2022-05-27 2023-05-26 Pending JPWO2023229032A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022087166 2022-05-27
PCT/JP2023/019755 WO2023229032A1 (ja) 2022-05-27 2023-05-26 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬

Publications (2)

Publication Number Publication Date
JPWO2023229032A1 JPWO2023229032A1 (cg-RX-API-DMAC7.html) 2023-11-30
JPWO2023229032A5 true JPWO2023229032A5 (cg-RX-API-DMAC7.html) 2026-06-02

Family

ID=88919516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523363A Pending JPWO2023229032A1 (cg-RX-API-DMAC7.html) 2022-05-27 2023-05-26

Country Status (5)

Country Link
US (1) US20250352541A1 (cg-RX-API-DMAC7.html)
EP (1) EP4534100A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023229032A1 (cg-RX-API-DMAC7.html)
CN (1) CN119403571A (cg-RX-API-DMAC7.html)
WO (1) WO2023229032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
EP4626433A1 (en) * 2022-11-29 2025-10-08 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CA3013514C (en) * 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
CA3135165A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.